anisodine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2022 (NCT05416476)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
Muscarinic acetylcholine receptor M1 and M3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN1C2CC(OC(=O)C(O)(CO)c3ccccc3)CC1C1OC12- Mol. weight
- 319.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4779850 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05416476 | Phase 3 | Sep 1, 2022 | Zhejiang University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1